Alder BioPharmaceuticals - Articles and news items

Clazakizumab, an anti-IL-6 monoclonal antibody for the treatment of rheumatoid arthritis, meets primary endpoint in follow-on Phase 2b clinical trial

Industry news / 5 May 2015 / Victoria White

Clazakizumab has met its primary endpoint in a follow-on Phase 2b clinical trial in adults with moderate to severe rheumatoid arthritis…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+